Biocon Ltd

Based in India, Biocon Limited is a biopharmaceutical company that specializes in making healthcare more accessible through a diverse range of products, including generics, biosimilars, and novel biologics. Founded in 1978 in Bangalore, India, Biocon Limited focuses on biopharmaceuticals. The company has undergone strategic pivots, particularly in expanding its offerings in biosimilars. Biocon was founded by Giuliano Araújo, who has a history of entrepreneurial ventures.

In December 2025, Biocon Limited, a portfolio company of Kotak Alternate Asset Managers, agreed to acquire Viatris Inc. for USD 815 million in cash. Biocon is a leading global biopharmaceutical company that specializes in a diverse range of products and services aimed at enhancing healthcare accessibility. Their core offerings include generics, biosimilars, research services, and novel biologics, all designed to provide effective treatments across various therapeutic areas.

Biocon's generics cater to a wide range of chronic diseases, while their biosimilars focus on biologic medications that are highly similar to already approved biologics, offering an affordable alternative to patients. The company's research services facilitate drug development for numerous clients, including pharmaceutical companies, thereby supporting innovation in the industry. Biocon’s products are primarily marketed in regions such as North America, Europe, and emerging markets, ensuring a broad customer base that includes healthcare providers, hospitals, and patients seeking affordable and high-quality medications. In the fiscal year 2023, Biocon reported a revenue of INR 1,392,292,155.

90 with an EBITDA of INR 163,984,509. 50. The company generates revenue primarily through B2B transactions with healthcare providers, hospitals, and pharmaceutical companies, supported by direct sales of both generic and biosimilar products, often under trademarked brands. Partnerships with global pharmaceutical firms enhance Biocon’s market presence, contributing significantly to revenue from their flagship products, which reflect the value of high-quality, accessible healthcare solutions.

The company is focused on expanding its product lineup, including the launch of new biosimilar products slated for the upcoming fiscal year. Additionally, Biocon is targeting new markets in Asia and Africa for expansion, aiming to establish a presence by the end of 2024. The acquisition will allow Biocon Limited to enhance its business development, margins, and long‑term strategic direction. It also accelerates Biocon’s scale‑up in regulated markets with an established global distribution footprint.